相关实验视频

Updated: Sep 11, 2025

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

在IBD中胺代谢:朝着精密营养

Dimitra Kanta¹, Eleftherios Katsamakas¹, Anna Maia Berg Gudiksen¹

¹Department of Nutrition, Exercise and Sports, University of Copenhagen, 1958 Frederiksberg, Denmark.

|August 14, 2025

概括

本综述探讨了炎症性肠病 (IBD) 和组胺素不耐受 (HIT) 之间的联系. 低组胺饮食 (LHD) 可以通过减少饮食和肠道微生物组胺来帮助管理IBD.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
营养科学营养科学

背景情况:

炎症性肠病 (IBD) 涉及免疫调节失调,可能会被组胺激素恶化.
目前的IBD饮食建议缺乏对组胺代谢和不耐受性的关注.
胰岛素不耐受 (HIT) 是肠道炎症的一个新兴考虑因素.

研究的目的:

审查IBD和基因组胺代谢之间的关系.
提出一种低组胺饮食 (LHD) 框架,用于在HIT患者中治疗IBD.
突出需要对IBD中的LHD进行临床试验.

主要方法:

现有文献的叙述性审查.
在PubMed/MEDLINE,谷歌学者,ScienceDirect,Scopus和科学网上进行了搜索.
拟议的LHD策略:减少饮食中的组胺和调节肠道微生物群.

主要成果:

在IBD患者的LHD研究中发现了一个缺口.
强调了像二胺氧化酶 (DAO) 和组胺-N-甲基转移酶 (HNMT) 这样的基因组胺降解酶的重要性.
目前还没有针对IBD群体的LHD干预的临床试验.

结论:

低组胺饮食 (LHD) 是一种新的饮食策略,用于治疗组胺不耐受症 (HIT) 患者的IBD.
未来的研究必须优先考虑临床试验,以评估LHD在IBD中的有效性和适用性.
了解组胺的作用和个体不耐受性对于个性化的IBD营养至关重要.

关键词:

克罗恩氏病是什么克罗恩氏病是什么达奥组织的达奥组织.IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD 基因组胺组胺的使用方法组织胺不耐受症组织胺不耐受症产生组胺的细菌产生组胺.低组胺饮食的饮食巨细胞激活活动营养营养营养营养性结肠炎是一种

更多相关视频

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...